PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
University of Melbourne · Peter MacCallum Cancer Centre · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
258
total citations
- FWCI
- 34.15
- Percentile
- 100%
- References
- 19
Citations per year
Authors
72- JPJames P ButeauCorresponding
University of Melbourne, Peter MacCallum Cancer Centre
- AMAndrew Martin
National Health and Medical Research Council, University of Sydney
- LELouise Emmett
UNSW Sydney, St Vincent's Hospital Sydney
- AIAmir Iravani
University of Melbourne, Peter MacCallum Cancer Centre
- SSShahneen Sandhu
University of Melbourne
Topics & keywords
Topics
Keywords
- Cabazitaxel
- Medicine
- Prostate cancer
- Docetaxel
- Enzalutamide
- Clinical endpoint
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.